Rafael Pharmaceuticals Announces Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach